Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:ALKS

Alkermes Q3 2026 Earnings Date & Estimates

Alkermes logo
$44.24 +0.76 (+1.74%)
As of 10:20 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Alkermes is estimated to report Q3 2026 earnings on Tuesday, October 27, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Alkermes in Q3 2026

Alkermes is expected to post earnings of -$0.0809 per share on revenue of $463.61 million. In the same quarter a year earlier Alkermes reported $0.49 per share on revenue of $394.19 million. Alkermes last reported on February 26, 2026, posting $0.29 per share and missing the $0.43 consensus estimate. Alkermes has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0809
Expected Revenue
$463.61 million
Prior-Year EPS
$0.49
Prior-Year Revenue
$394.19 million
Expected EPS Growth
-116.5%
Expected Revenue Growth
+17.6%

Recent Track Record

Last Reported
Q4 2025
Last Quarter EPS
$0.29 (Missed by -$0.14)
Last Quarter Revenue
$384.55 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Alkermes Q3 2026 Earnings FAQ

Alkermes (NASDAQ:ALKS) is estimated to report Q3 2026 earnings on Tuesday, October 27, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Alkermes' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Alkermes to post earnings of -$0.0809 per share for Q3 2026.

The consensus revenue estimate for Alkermes is $463.61 million for Q3 2026.

Alkermes Earnings Headlines

Alkermes (ALKS) Expected to Post Earnings on Wednesday
October 21 at 3:42 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31142061
Alkermes (ALKS) Receives a Buy from Needham
October 20 at 10:24 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ALKS/pressreleases/8227039/alkermes-alks-receives-a-buy-from-needham/
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
October 22 at 1:00 AM  |  Weiss Ratings (Ad)
Alkermes to Report Third Quarter Financial Results on November 3, 2026
October 20 at 10:24 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/alkermes-report-third-quarter-financial-200000158.html
Truist Financial Begins Coverage on Alkermes (NASDAQ:ALKS)
October 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31129679
Alkermes plc (NASDAQ:ALKS) Stock Has Consensus Price Target of $54.47
October 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31127495
See More Alkermes Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alkermes? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alkermes and other key companies, straight to your email.

About Alkermes

Alkermes (NASDAQ:ALKS) (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.

The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts. The company serves patients primarily through the United States pharmaceutical market and uses proprietary drug-delivery technologies, including long-acting injectable formulations, as part of its approach to developing treatments for complex and chronic conditions.

View Alkermes Profile
Earnings Tools